Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma
暂无分享,去创建一个
[1] Sakkarin Chirapongsathorn,et al. Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study , 2021, World journal of clinical cases.
[2] Xin Yang,et al. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization , 2021, Journal of Cancer Research and Therapeutics.
[3] F. A. Moura,et al. N-Acetylcysteine (NAC): Impacts on Human Health , 2021, Antioxidants.
[4] R. Vilaichone,et al. N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization , 2019, Digestive Diseases and Sciences.
[5] M. Abecassis,et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.
[6] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[7] O. Yokosuka,et al. A randomized placebo‐controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization , 2018, Hepatology.
[8] J. Jang,et al. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. , 2017, Journal of vascular and interventional radiology : JVIR.
[9] J. Hansmann,et al. Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma. , 2017, Journal of vascular and interventional radiology : JVIR.
[10] A. Webster,et al. Probiotics for people with hepatic encephalopathy. , 2017, The Cochrane database of systematic reviews.
[11] H. Blackburn,et al. Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer , 2016, Cancer nursing.
[12] S. Temin,et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice / American Society of Clinical Oncology.
[13] Liyong Pu,et al. N-acetylcysteine attenuates reactive-oxygen-species-mediated endoplasmic reticulum stress during liver ischemia-reperfusion injury. , 2014, World journal of gastroenterology.
[14] Fan Wang,et al. N-Acetylcysteine Attenuates Ischemia-Reperfusion-Induced Apoptosis and Autophagy in Mouse Liver via Regulation of the ROS/JNK/Bcl-2 Pathway , 2014, PloS one.
[15] J. Chiu,et al. Protective Effects of N-acetylcysteine and a Prostaglandin E1 Analog, Alprostadil, Against Hepatic Ischemia: Reperfusion Injury in Rats , 2014, Journal of traditional and complementary medicine.
[16] R. Vilaichone,et al. Epidemiology and survival of hepatocellular carcinoma in the central region of Thailand. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[17] D. Hippe,et al. Postembolization syndrome after hepatic transarterial chemoembolization: effect of prophylactic steroids on postprocedure medication requirements. , 2013, Journal of vascular and interventional radiology : JVIR.
[18] Seonwoo Kim,et al. Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[19] E. Garwood,et al. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[20] Z. Abbas,et al. Adverse events following transarterial chemoembolization for hepatocellular carcinoma and factors predicting such events. , 2013, JPMA. The Journal of the Pakistan Medical Association.
[21] M. Rudler,et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. , 2011, The New England journal of medicine.
[22] M. Kris,et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Chia-Yang Hsu,et al. Liver Failure After Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma and Ascites: Incidence, Risk Factors, and Prognostic Prediction , 2011, Journal of clinical gastroenterology.
[24] William M. Lee,et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. , 2009, Gastroenterology.
[25] Shou-Dong Lee,et al. Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis , 2008, Scandinavian journal of gastroenterology.
[26] Stephanie Green,et al. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.
[27] R. Parks,et al. Postchemoembolisation syndrome – tumour necrosis or hepatocyte injury? , 2003, British Journal of Cancer.
[28] F. Chang,et al. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test , 2002, American Journal of Gastroenterology.
[29] M. Yuen,et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma , 2002, Cancer.
[30] D. Leung,et al. Determinants of postembolization syndrome after hepatic chemoembolization. , 2001, Journal of vascular and interventional radiology : JVIR.
[31] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[32] J. Critchley,et al. The treatment of acetaminophen poisoning. , 1983, Annual review of pharmacology and toxicology.
[33] M. Dumont,et al. European Association for the Study of the Liver , 1971 .